← 홈

IBD (크론·대장) · IL-12 / IL-23

14개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 14개
AntibodySHOTFDACuratedFDABiologicJanssenApproved

ustekinumab (Stelara, Wezlana)

Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)

#IL-12IL-23p40#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 75%임상시험 116상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAbbVieApproved

risankizumab (Skyrizi)

Psoriasis, psoriatic arthritis, Crohn's disease · IL-23 (p19)

#IL-23p19#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 90%임상시험 73상태 APPROVED
AntibodyUniversity of CalgaryApproved

ustekinumab (Stelara, Anti-IL12/23 or anti-IL23 - Ustekinumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+2
임상시험 4상태 RECRUITING
AntibodyUniversity of CalgaryApproved

Anti-IL12/23 or anti-IL23 - Risankizumab (Anti-IL12/23 or anti-IL23 - Risankizumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodystaleJanssenApproved

ustekinumab (Stelara, 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab))

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenApproved

ustekinumab (Stelara, 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenApproved

ustekinumab (Stelara, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenApproved

ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleFundación de Investigación Biom…Preclinical

ustekinumab (Stelara, Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab)

Inflammatory Bowel Disease · Inflammatory Bowel Disease

#InflammatoryBowelDisease#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJanssenApproved

ustekinumab (Stelara, Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib)

Inflammatory Bowel Diseases; Crohn Disease · Inflammatory Bowel Diseases

#InflammatoryBowelDiseases#Antibody#Approved#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleJanssenPreclinical

UST (Ustekinumab, Ustekinumab (UST))

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Preclinical#항체#면역항체+2
효능 ORR 3%임상시험 1상태 ACTIVE
AntibodystaleJanssenPreclinical

ustekinumab (Stelara, Ustekinumab - Standard Dosage)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePreclinical

ustekinumab (Stelara, adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab)

Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) · Inflamatory Bowel Disease (Crohn's a

#InflamatoryBowelDiseaseCrohn39sa#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPreclinical

ustekinumab (Stelara, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab)

Ulcerative Colitis · Ulcerative Colitis

#UlcerativeColitis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE